Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving a-blocker treatment for lower urinary tract symptoms

被引:44
|
作者
Kaplan, Steven A. [1 ]
Roehrborn, Claus G. [2 ]
Gong, Jason [3 ]
Sun, Franklin [3 ]
Guan, Zhonghong [3 ]
机构
[1] Cornell Univ, Dept Urol, Weill Cornell Med Coll, New York, NY 10021 USA
[2] UT SW Med Ctr Dallas, Dept Urol, Dallas, TX USA
[3] Pfizer Inc, New York, NY USA
关键词
a-blocker; antimuscarinic; fesoterodine; prostatic hyperplasia; LUTS; men; overactive bladder; signs and symptoms; TOLTERODINE EXTENDED-RELEASE; PROSTATE-SPECIFIC ANTIGEN; QUALITY-OF-LIFE; OUTLET OBSTRUCTION; TAMSULOSIN; VALIDATION; EFFICACY; INCONTINENCE; TERMINOLOGY; COMBINATION;
D O I
10.1111/j.1464-410X.2011.10624.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Study Type Therapy (RCT) Level of Evidence 1b What's known on the subject? and What does the study add? Male lower urinary tract symptoms are often attributed to bladder outlet obstruction secondary to benign prostatic hyperplasia and treated with drugs targeting the prostate. However, many men with storage lower urinary tract symptoms may not respond adequately to these agents. Antimuscarinics, with or without an a-blocker, may be effective for the treatment of the storage symptoms of overactive bladder in some men. Flexible-dose fesoterodine as an add-on treatment significantly improved urinary frequency and symptom bother, but not urgency episodes (primary endpoint), versus add-on placebo and was well tolerated in men with persistent overactive bladder symptoms despite receiving a-blocker. OBJECTIVE To evaluate flexible-dose fesoterodine vs placebo in men with persistent overactive bladder (OAB) symptoms despite receiving a-blocker treatment SUBJECTS AND METHODS This was a double-blind, 12-week, flexible-dose trial. Men with persistent storage symptoms (=8 micturitions and =3 urgency episodes per 24 h) after receiving an a-blocker for =6 weeks were randomized to add-on fesoterodine 4 mg or placebo, with optional dose escalation to 8 mg at week 4 and reduction back to 4 mg at week 8 (or matching placebo adjustments). Subjects completed 3-day diaries, International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), and Urgency Perception Scale (UPS) at baseline and weeks 4 and 12. RESULTS A total of 943 men were randomized and received at least one dose of study treatment (fesoterodine, n= 471; placebo, n= 472). Among these, 251 (53%) in the fesoterodine group and 300 (64%) in the placebo group requested dose escalation at week 4 and 35 (7%) and 15 (3%) requested dose reduction at week 8. Changes from baseline to week 12 in urgency episodes (primary endpoint) in the fesoterodine (-3.2) and placebo (-2.9) groups were not significantly different (P= 0.196), but improvements in micturitions (P= 0.009) and OAB-q symptom bother score (P= 0.007) were significantly greater with fesoterodine. At week 4, significantly greater improvements in micturitions (P= 0.006), severe urgency episodes (P= 0.006), IPSS storage score (P= 0.022), OAB-q symptom bother score (P= 0.004), and OAB-q health-related quality of life (P= 0.041), but not urgency episodes (P= 0.062), were observed with add-on fesoterodine. Dry mouth (fesoterodine, 21%; placebo, 6%) and constipation (fesoterodine, 6%; placebo, 2%) were the most common adverse events. Dysuria and urinary retention were reported by 3% and 2% of subjects, respectively, in the fesoterodine add-on group vs 1% and <1% of subjects, respectively in the placebo add-on group. One subject in each group had acute urinary retention requiring catheterization. CONCLUSIONS Flexible-dose fesoterodine was well tolerated as an add-on treatment in men with persistent storage symptoms. Changes in urgency episodes at week 12 (primary endpoint) and many secondary endpoints were not significantly different between fesoterodine and placebo add-on treatment; however, improvements in frequency and symptom bother were significantly greater with fesoterodine. These data suggest that there remains a limited understanding of the optimal evaluation and treatment of men with LUTS.
引用
收藏
页码:1831 / 1840
页数:10
相关论文
共 50 条
  • [1] Treatment of men with lower urinary tract symptoms and overactive bladder
    Bell, William Andrew
    Amarshi, Naseem
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (11): : 1192 - 1192
  • [2] Factors contributing to the efficacy of two add-on therapies of fesoterodine or mirabegron to silodosin monotherapy for persistent overactive bladder in men with lower urinary tract symptoms
    Matsukawa, Yoshihisa
    Gotoh, Momokazu
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (01) : 85 - 86
  • [3] Add-on tolterodine extended release improves overactive bladder symptoms in men receiving α-blocker therapy
    Herschorn, Sender
    Abrams, Paul
    Chapple, Christopher R.
    Sun, Franklin
    Brodsky, Marina
    Guan, Zhonghong
    JOURNAL OF UROLOGY, 2008, 179 (04): : 443 - 443
  • [4] Treatment of men with lower urinary tract symptoms and overactive bladder - Reply
    Kaplan, Steven A.
    Roehrborn, Claus G.
    Rovner, Eric S.
    Bavendam, Tamara
    Guan, Zhonghong
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (11): : 1193 - 1193
  • [5] Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Lower Urinary Tract Symptoms-ASSIST, Randomized Controlled Study
    Yamaguchi, Osamu
    Kakizaki, Hidehiro
    Homma, Yukio
    Takeda, Masayuki
    Nishizawa, Osamu
    Gotoh, Momokazu
    Yokoyama, Osamu
    Seki, Narihito
    Yoshida, Masaki
    UROLOGY, 2011, 78 (01) : 126 - 133
  • [6] The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
    Masumori, Naoya
    Tsukamoto, Taiji
    Yanase, Masahiro
    Horita, Hiroki
    Aoki, Masaharu
    ADVANCES IN UROLOGY, 2010, 2010
  • [7] Management of overactive bladder and lower urinary tract symptoms in men
    Hamilton J.N.
    Rovner E.S.
    Current Bladder Dysfunction Reports, 2008, 3 (2) : 117 - 122
  • [8] Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo -controlled Study (MATCH)
    Kakizaki, Hidehiro
    Lee, Kyu-Sung
    Yamamoto, Osamu
    Jong, Jar Jar
    Katou, Daisuke
    Sumarsono, Budiwan
    Uno, Satoshi
    Yamaguchi, Osamu
    EUROPEAN UROLOGY FOCUS, 2020, 6 (04): : 729 - 737
  • [9] Add-On tolterodine extended release improves overactive bladder symptoms in men receiving alpha-blocker therapy
    Chapple, C.
    Abrams, P.
    Herschorn, S.
    Sun, F.
    Brodsky, M.
    Guan, Z.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 239 - 239
  • [10] Desmopressin Add-On Therapy for Refractory Nocturia in Men Receiving α-Blockers for Lower Urinary Tract Symptoms
    Bae, Woong Jin
    Bae, Jang Ho
    Kim, Sae Woong
    Chung, Byung Ha
    Kim, Jang Hwan
    Kim, Choung Soo
    Lee, Hyun Moo
    Lee, Kyung Seop
    Yoo, Tag Keun
    Kim, Sun Il
    Byun, Seok Soo
    Lee, Ji Youl
    JOURNAL OF UROLOGY, 2013, 190 (01): : 180 - 186